UPDATE 2-Hikma shares jump after improved sales outlook, COVID-19 drug deal
* H1 core operating profit up 15% to $284 million* Raises sales forecast for two main divisions* Signs deal to manufacture Gilead's remdesivir* Profit tops company's expectations - CEO* Shares jump 11%, biggest pct gainer on FTSE 100 (Writes through...
